Ergothioneine concept stocks attract attention, multiple companies respond

Recently, ergotamine concept stocks have emerged strongly, with several listed companies responding to related questions on interactive platforms. ① Chengzhi: The company's ergotamine is still in the small-scale testing phase. ② SIRIO: The company's U.S. subsidiary Best Formulations has the capability to produce NAD+ ergotamine cell energy capsules. The company is very optimistic about the development potential of the anti-aging market. In addition to ergotamine, the company has also laid out related products such as PQQ, quercetin, and Q10 that can be applied in anti-aging scenarios. In February of this year, the company announced the establishment of an anti-aging research institute, aiming to focus on "scientific research innovation + industrial transformation," with a focus on four major areas: cellular systems, probiotics and the gut, muscle joints, and women's ovaries. ③ WanBang Pharmaceutical: The company provides clinical efficacy testing services for an ergotamine eye wash project aimed at improving dry eye syndrome. ④ FUSHILAI: The company currently has no ergotamine-related business

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.